Description

In rare instances, certain vaccinations have been associated with a condition known as Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). This immune-mediated condition involves abnormal blood clotting (thrombosis) and low platelet levels (thrombocytopenia), driven by immune system responses to platelet factor 4 (PF4).

This panel evaluates critical biomarkers to help detect or rule out VITT and differentiate it from other causes of thrombosis or low platelets.

Symptoms of Possible VITT (Typically Within 4–30 Days Post Vaccination):

  • Persistent or severe headache
  • Visual changes
  • Abdominal pain
  • Chest pain
  • Shortness of breath
  • Swelling or pain in limbs
  • Unusual bruising or bleeding
  • Neurological symptoms (e.g., confusion, seizures)

This Panel Includes the Following Biomarkers:

Anti-Platelet Factor 4 (Anti-PF4) Antibodies (ELISA-based)

  • Purpose: Detects antibodies to PF4, a key marker in VITT.
  • Why it matters: Positive Anti-PF4 by ELISA is strongly associated with VITT. It helps differentiate VITT from other platelet disorders, including Heparin-Induced Thrombocytopenia (HIT), which requires different management.

Complete Blood Count (CBC)

  • Purpose: Measures levels of red and white blood cells and platelets.
  • Why it matters: Thrombocytopenia (low platelet count) is a hallmark of VITT. CBC also screens for other hematologic abnormalities that could suggest different causes of symptoms.

D-dimer

  • Purpose: Measures breakdown products of blood clots.
  • Why it matters: VITT is often associated with markedly elevated D-dimer levels, indicating abnormal clot formation and breakdown throughout the body.

Fibrinogen

  • Purpose: Assesses levels of a key clotting protein produced by the liver.
  • Why it matters: In VITT, fibrinogen levels may be reduced due to widespread clotting activity. It helps assess the severity of the coagulation disturbance.

Test Preparation:

  • Fasting: Not required
  • Sample Type: Blood (venipuncture)

Who Should Consider This Panel:

  • Individuals experiencing thrombotic symptoms within 30 days post-vaccination
  • Those with a low platelet count of unknown cause
  • Patients with elevated D-dimer without a clear diagnosis
  • People concerned about post-vaccine adverse effects and seeking a full vascular screening
  • Clinicians evaluating potential vaccine-related thrombotic disorders

Why This Panel Matters:

While VITT is extremely rare, early and accurate diagnosis is essential due to the potential severity of clotting complications. This panel includes the core biomarkers used in clinical algorithms worldwide for diagnosing or ruling out VITT, supporting providers with timely and informed treatment decisions.

If you've experienced unusual symptoms after vaccination or have concerns about clotting risks, this test offers vital insight and peace of mind.